EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Chromogranin A as a diagnostic marker of pheochromocytoma and paraganglioma: A systematic review and meta‐analysis

Yanbo Xing iD, Haoying Shi, Qiang Guo, Cong Wang, Chengyong Li, Chuan Hao iD

International Journal of Urology · 2024-06 · 31 (6) · 637-645

DOI: 10.1111/iju.15423 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift International Journal of Urology, online erschienen am 21.02.2024. Verfasst von Yanbo Xing und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. Hauptthemen laut MEDLINE: Pheochromocytoma, Chromogranin A, Adrenal Gland Neoplasms, Paraganglioma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This work aims to assess the diagnostic value of chromogranin A (CgA) in the laboratory diagnosis of neuroendocrine tumors classified as pheochromocytoma and paraganglioma (PPGL).

Methods

A comprehensive search was performed in PubMed, Embase, the Cochrane Library, and Web of Science databases to obtain relevant studies reporting the diagnostic accuracy of CgA in patients with PPGL. The search involved studies written in English between the time of library inception and May 1, 2023. We computed the pooled sensitivity, specificity, and diagnostic odds ratio (DOR). Additionally, the receiver operating characteristic curve and area under the curve (AUC) were determined. The heterogeneity was assessed using the Chi‐square test and the I 2 test. The subgroup analyses were performed to investigate the origins of heterogeneity. Stata 15.1 statistical software was used in all data analyses.

Results

This meta‐analysis included 13 studies involving 1470 patients. CgA had a pooled diagnostic sensitivity of 0.86 (95% CI 0.81–0.91), a specificity of 0.90 (95% CI 0.81–0.95), and a DOR of 57 (95% CI 23–142). CgA had an AUC of 0.93. The studies did not reveal any threshold effect ( r = −0.165; p > 0.05). The subgroup analyses revealed that the control group category and the detection method caused the overall heterogeneity.

Conclusions

Our study suggests that CgA is a helpful PPGL biomarker. However, relying solely on CgA for diagnosis is not advisable. A comprehensive approach is essential for accurate diagnosis. Future large‐scale research is needed to refine CgA's clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PheochromocytomaChromogranin AAdrenal Gland NeoplasmsParagangliomaBiomarkers, TumorSensitivity and SpecificityHumansROC Curve

Stichwörter der Autor:innen

chromogranin Adiagnostic accuracymeta‐analysisparagangliomapheochromocytomasystematic review

Substanzen

Chromogranin ABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
  • Second Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China.

ORCID-Profile: Yanbo Xing, Chuan Hao

Zitieren

APA

Xing, Y., Shi, H., Guo, Q., Wang, C., Li, C., & Hao, C. (2024). Chromogranin A as a diagnostic marker of pheochromocytoma and paraganglioma: A systematic review and meta‐analysis. International Journal of Urology, 31(6), 637-645. https://doi.org/10.1111/iju.15423

Vancouver

Xing Y, Shi H, Guo Q, Wang C, Li C, Hao C. Chromogranin A as a diagnostic marker of pheochromocytoma and paraganglioma: A systematic review and meta‐analysis. International Journal of Urology. 2024;31(6):637-645. doi:10.1111/iju.15423

BibTeX
@article{Xing2024,
  author = {Xing, Yanbo and Shi, Haoying and Guo, Qiang and Wang, Cong and Li, Chengyong and Hao, Chuan},
  title = {Chromogranin A as a diagnostic marker of pheochromocytoma and paraganglioma: A systematic review and meta‐analysis},
  journal = {International Journal of Urology},
  year = {2024},
  volume = {31},
  number = {6},
  pages = {637--645},
  doi = {10.1111/iju.15423}
}
Kostenlos starten →